Document Detail


Effects of small doses of bisoprolol on blood pressure and lipoprotein concentrations in hypertensive patients.
MedLine Citation:
PMID:  8436149     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of bisoprolol 2.5 and 5 mg per day on blood pressure, and lipoprotein and apolipoprotein concentrations were compared in 18 newly detected hypertensives in a double-blind, crossover study. All treatment results were related to the values at the end of a four-week placebo run-in period. Each of the two following treatment periods lasted for 3 months. The systolic and diastolic pressures in the supine position were reduced by 19.5/11.7 mm Hg and 14.6/10.4 mm Hg by 2.5 and 5 mg bisoprolol per day, respectively, with no significant difference in effect. Supine heart rate was reduced by 4.7 and 8.2 beats.min-1, respectively, (P = 0.0517 for different effects). The cholesterol concentration in low-density (LDL) and high-density (HDL) lipoproteins was reduced during both regimens, by about 0.3 and 0.1 mmol.l-1, respectively, difference not significant. Triglyceride concentrations were not significantly affected during either regimen. We conclude that, in this study population, treatment with bisoprolol 2.5 mg per day was equally effective as 5.0 mg per day in reducing blood pressure. The effects on lipoprotein concentrations were small and included an unexpected reduction in LDL-cholesterol concentration. A low dose of a highly selective beta-adrenoceptor blocker like bisoprolol appears to retain the blood pressure reducing capacity and has lost most of the unfavourable effects on lipoproteins characteristic of higher doses.
Authors:
H Lithell; L Weiner; B Vessby; M L Nordström
Related Documents :
8299449 - Blood pressure, insulin, and c-peptide levels in san luis valley, colorado.
14508189 - Increased c-reactive protein concentrations in never-treated hypertension: the role of ...
9672509 - Nocturnal blood pressure in young patients with insulin-dependent diabetes mellitus: co...
7768579 - Serum n-acetyl-beta-d-glucosaminidase activity in predicting the development of hyperte...
9100089 - Osteoarthritis as a determinant of an adverse coronary heart disease risk profile.
9309419 - Prevalence of peripheral arterial disease in an elderly rural population of southern it...
7511749 - Effects of endothelin-1 at pathophysiologic concentrations on coronary perfusion and me...
17747489 - Effect of a coordination change on the strength of amorphous sio2.
22757779 - On the origin of photoluminescence in silicon nanocrystals: pressure-dependent structur...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  44     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  1993  
Date Detail:
Created Date:  1993-03-23     Completed Date:  1993-03-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  19-22     Citation Subset:  IM    
Affiliation:
Institute of Geriatrics, Uppsala University, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Bisoprolol / administration & dosage*,  pharmacology
Blood Pressure / drug effects*
Cholesterol, HDL / blood
Cholesterol, LDL / blood,  drug effects
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Hypertension / blood,  drug therapy*,  physiopathology
Lipoproteins / blood*,  drug effects
Male
Middle Aged
Supine Position
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Lipoproteins; 66722-44-9/Bisoprolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Enalapril versus atenolol in the treatment of hypertensive smokers.
Next Document:  Antihypertensive effect of once daily sustained release isradipine: a placebo controlled cross-over ...